JO3019B1 - ثلاثي مستبدل 4،2،1-ثلاثي زولات - Google Patents

ثلاثي مستبدل 4،2،1-ثلاثي زولات

Info

Publication number
JO3019B1
JO3019B1 JOP/2007/0105A JOP20070105A JO3019B1 JO 3019 B1 JO3019 B1 JO 3019B1 JO P20070105 A JOP20070105 A JO P20070105A JO 3019 B1 JO3019 B1 JO 3019B1
Authority
JO
Jordan
Prior art keywords
positive allosteric
trisubstituted
triazoles
relates
analogues
Prior art date
Application number
JOP/2007/0105A
Other languages
English (en)
Inventor
Simone Josephine Lesage Anne
Emiel Maria Van Roosroeck Yves
Dinklo Theodorus
James Macdonald Gregor
Wilhelmus John F Thuring Johannes
Edward Stewart Duffy James
Alfons Maria Van Den Keybus Frans
Frans Leopold De Bruyn Marcel
Zhuang Wei
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3019B1 publication Critical patent/JO3019B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بمشتقات 3- انيلين -5- اريل ترايازول ( 3-ANILINE -5-ARYL TRIAZOLE) و بمواد مماثلة (ANALOGUES ) او باملاح ( SALTS) مقبوله دوائيا منها ، بعمليات (PROCESSES) لتحضيرها ، بتركيبات دوائية ( pharmaceutical Compositions) تحتويها و باستخدامها في العلاج، طبقا للصيغة(1). يتعلق الاختراع تحديدا بمواد ضابطة متباينة الفراغية موجبة (positive allosteric modulators) لمستقبلات استيل كولين نيكوتينية ( nicotinic acetylcholine receptors ) ، و هذه المواد الضابطة متباينة الفراغية الموجبة لها القدرة على زيادة فعالية معضدات مستقبل نيكوتيني (nicotinic receptor agonists) .
JOP/2007/0105A 2006-04-19 2007-04-03 ثلاثي مستبدل 4،2،1-ثلاثي زولات JO3019B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06112754 2006-04-19

Publications (1)

Publication Number Publication Date
JO3019B1 true JO3019B1 (ar) 2016-09-05

Family

ID=37814207

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2007/0105A JO3019B1 (ar) 2006-04-19 2007-04-03 ثلاثي مستبدل 4،2،1-ثلاثي زولات

Country Status (21)

Country Link
US (1) US8143419B2 (ar)
EP (1) EP2010516B1 (ar)
JP (1) JP5439169B2 (ar)
KR (1) KR101465413B1 (ar)
CN (1) CN101472911B (ar)
AR (1) AR060537A1 (ar)
AU (1) AU2007239498B2 (ar)
BR (1) BRPI0710819A2 (ar)
CA (1) CA2648157C (ar)
EA (1) EA016289B1 (ar)
ES (1) ES2501946T3 (ar)
IL (1) IL194744A (ar)
JO (1) JO3019B1 (ar)
MX (1) MX2008013457A (ar)
MY (1) MY147212A (ar)
NO (1) NO342797B1 (ar)
NZ (1) NZ572468A (ar)
TW (1) TWI408132B (ar)
UA (1) UA95281C2 (ar)
WO (1) WO2007118903A1 (ar)
ZA (1) ZA200808916B (ar)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات
WO2008028903A2 (en) * 2006-09-04 2008-03-13 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
CA2697974C (en) * 2007-10-18 2015-06-30 Janssen Pharmaceutica Nv Trisubstituted 1,2,4-triazoles
JO2784B1 (ar) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في مشتق 5,3,1 - ثلاثي مستبدل ترايازول
WO2009115547A1 (en) * 2008-03-19 2009-09-24 Janssen Pharmaceutica Nv Trisubstituted 1, 2, 4 -triazoiies as nicotinic acetylcholine receptor modulators
AR071763A1 (es) 2008-05-09 2010-07-14 Janssen Pharmaceutica Nv Pirazoles trisustituidos, composiciones farmaceuticas que los contienen, y usos de los mismos en el tratamiento de trastornos neurologicos y psiquiatricos
JP5636428B2 (ja) * 2009-09-17 2014-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ 置換ｎ−フェニル−１−（４−ピリジニル）−１ｈ−ピラゾル−３−アミン類
JO3078B1 (ar) * 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
KR20140041442A (ko) 2011-02-03 2014-04-04 루핀 리미티드 알파 7 ｎａｃｈｒ의 조절자로 사용된 피롤 유도체
EA024170B1 (ru) 2011-02-23 2016-08-31 Люпин Лимитед ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ nAChR АЛЬФА7
SG192939A1 (en) 2011-02-25 2013-09-30 Janssen Pharmaceutica Nv PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR
EP2691368A1 (en) 2011-03-31 2014-02-05 Lupin Limited Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's disease
EP2729455B1 (en) 2011-07-05 2016-09-14 Lupin Limited Biaryl derivatives as nachr modulators
EP2822946A1 (en) 2012-03-06 2015-01-14 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
US20150299178A1 (en) 2012-11-12 2015-10-22 Lupin Limited Thiazole Derivatives as Alpha 7 NACHR Modulators
US9617211B2 (en) 2013-01-16 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
AU2014229300A1 (en) 2013-03-13 2015-06-11 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
TW201446243A (zh) 2013-06-03 2014-12-16 Lupin Ltd 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑
AU2014282886A1 (en) 2013-06-17 2015-12-17 Lupin Limited Pyrrole derivatives as alpha 7 nAChR modulators
ES2796276T3 (es) * 2015-02-05 2020-11-26 Ab Science Compuestos con actividad antitumoral
CN110835336B (zh) * 2018-08-16 2022-10-04 中国药科大学 含氧杂环取代唑类化合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3773746D1 (en) 1986-05-07 1991-11-21 Fisons Plc Pyrazole.
FR2792314B1 (fr) 1999-04-15 2001-06-01 Adir Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE257827T1 (de) * 1999-07-21 2004-01-15 Hoffmann La Roche Triazolderivate
FR2802530B1 (fr) 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
MXPA04010966A (es) 2002-05-07 2005-01-25 Neurosearch As Derivados novedosos de biarilo diazabiciclico.
JP4711391B2 (ja) * 2002-09-30 2011-06-29 ニューロサーチ、アクティーゼルスカブ 新規１，４−ジアザビシクロアルカン誘導体及びその製造方法
WO2005004818A2 (en) * 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
WO2005012263A1 (en) * 2003-07-24 2005-02-10 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
FR2862647B1 (fr) 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
WO2006064375A2 (en) 2004-12-16 2006-06-22 Ab Science Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases
AU2006290814B2 (en) 2005-09-13 2012-06-07 Janssen Pharmaceutica N.V. 2-aniline-4-aryl substituted thiazole derivatives
JO3019B1 (ar) 2006-04-19 2016-09-05 Janssen Pharmaceutica Nv ثلاثي مستبدل 4،2،1-ثلاثي زولات

Also Published As

Publication number Publication date
WO2007118903A1 (en) 2007-10-25
NO20084744L (no) 2008-11-10
IL194744A (en) 2016-10-31
JP5439169B2 (ja) 2014-03-12
IL194744A0 (en) 2009-08-03
UA95281C2 (en) 2011-07-25
ES2501946T3 (es) 2014-10-02
MX2008013457A (es) 2008-10-30
NZ572468A (en) 2010-07-30
KR101465413B1 (ko) 2014-12-01
EP2010516A1 (en) 2009-01-07
CA2648157C (en) 2012-04-03
CN101472911A (zh) 2009-07-01
CN101472911B (zh) 2014-07-02
US8143419B2 (en) 2012-03-27
AU2007239498A1 (en) 2007-10-25
CA2648157A1 (en) 2007-10-25
TWI408132B (zh) 2013-09-11
AU2007239498B2 (en) 2012-08-23
US20090253691A1 (en) 2009-10-08
BRPI0710819A2 (pt) 2011-08-23
EP2010516B1 (en) 2014-07-02
JP2009534357A (ja) 2009-09-24
HK1135375A1 (en) 2010-06-04
EA200870448A1 (ru) 2009-02-27
ZA200808916B (en) 2011-12-28
EA016289B1 (ru) 2012-03-30
TW200815396A (en) 2008-04-01
NO342797B1 (no) 2018-08-06
MY147212A (en) 2012-11-14
AR060537A1 (es) 2008-06-25
KR20090008335A (ko) 2009-01-21

Similar Documents

Publication Publication Date Title
JO3019B1 (ar) ثلاثي مستبدل 4،2،1-ثلاثي زولات
UA102681C2 (ru) Тризамещенные 1,2, 4-триазолы как модуляторы никотиновых ацетилхолиновых рецепторов
MY160728A (en) Morpholinothiazoles as alpha 7 positive allosteric modulators
PT2038290E (pt) Moduladores de receptor do tipo toll 7
JO2784B1 (ar) مشتق 5,3,1 - ثلاثي مستبدل ترايازول
MX2009013832A (es) Derivados de purina y su uso como moduladores del receptor 7 similar a un puente.
TW200517106A (en) Sustained release pharmaceutical compositions
MY163126A (en) 1,2,3-triazole derivatives for use as stearoyl-coa desaturase inhibitors
TW200833370A (en) Pharmaceutical composition containing low substituted hydroxypropylcellulose
MX2009005357A (es) Derivados de hidantoina usados como inhibidores de metaloproteinasas de matriz.
EA201071288A1 (ru) Тризамещенные пиразолы в качестве модуляторов рецепторов ацетилхолина
JO2800B1 (ar) مركبات تتراهيد روسيكلوبتا [b] اندول منظمات لمستقل الاندروجين
WO2007120575A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
MX2010003923A (es) Formulacion farmaceutica de valsartan.
TW200637874A (en) Peptides with neuropeptide-2 receptor (Y2R) agonist activity
MX2009004745A (es) Derivados de 1,2,3-triazol como inhibidores del receptor sigma.
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MX345656B (es) (piridin-4-il)bencilamidas como moduladores alostericos de nachr alfa 7.
EA201270428A1 (ru) Замещенные n-фенил-1-(4-пиридинил)-1н-пиразол-3-амины
GEP20125382B (en) New benzamide derivatives as bradykinin antagonists
MY141024A (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2006057922A3 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
TW200639156A (en) New compounds
MX2010004177A (es) 1,2,4-triazoles trisustituidos.
MX2020013291A (es) Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis.